138 related articles for article (PubMed ID: 19103739)
1. Regression of parathyroid hyperplasia by calcimimetics--fact or illusion?
Komaba H; Fukagawa M
Nephrol Dial Transplant; 2009 Mar; 24(3):707-9. PubMed ID: 19103739
[No Abstract] [Full Text] [Related]
2. Calcimimetics for predialysis patients?
Fournier A; Shahapuni I; Harbouche L; Monge M
Am J Kidney Dis; 2006 Jan; 47(1):196; author reply 196-7. PubMed ID: 16377407
[No Abstract] [Full Text] [Related]
3. Regression of parathyroid gland swelling by treatment with cinacalcet.
Terawaki H; Nakano H; Takeguchi F; Hasegawa T; Nakayama M; Okazaki M; Hosoya T
Nephrol Dial Transplant; 2009 Feb; 24(2):690-1; author reply 691-2. PubMed ID: 18987257
[No Abstract] [Full Text] [Related]
4. Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients.
Drüeke TB; Landais P
Am J Kidney Dis; 2006 Jun; 47(6):1083; author reply 1083-4. PubMed ID: 16731305
[No Abstract] [Full Text] [Related]
5. Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients.
Hirai T; Nakashima A; Takasugi N; Yorioka N
Ther Apher Dial; 2010 Dec; 14(6):577-82. PubMed ID: 21118366
[TBL] [Abstract][Full Text] [Related]
6. Tertiary hyperparathyroidism resistant to cinacalcet treatment.
Okada M; Tominaga Y; Izumi K; Nobata H; Yamamoto T; Hiramitsu T; Tsujita M; Goto N; Nanmoku K; Watarai T; Uchida K
Ther Apher Dial; 2011 Jun; 15 Suppl 1():33-7. PubMed ID: 21595850
[TBL] [Abstract][Full Text] [Related]
7. Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
Stubbs JR; Wetmore JB
Semin Dial; 2011; 24(3):298-306. PubMed ID: 21682772
[TBL] [Abstract][Full Text] [Related]
8. [Basic and clinical aspects of calcimimetics. Cinacalcet, effect and mechanisms of action].
Nakanishi S; Fukagawa M
Clin Calcium; 2008 Jan; 18(1):20-6. PubMed ID: 18175867
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
[TBL] [Abstract][Full Text] [Related]
11. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease.
Fukagawa M; Nakanishi S; Kazama JJ
Kidney Int Suppl; 2006 Jul; (102):S3-7. PubMed ID: 16810308
[TBL] [Abstract][Full Text] [Related]
12. Massive soft tissue calcifications in severe hyperparathyroidism secondary to end-stage renal disease.
Staszków M; Wojtaszek E; Żebrowski P; Matuszkiewicz-Rowińska J
Pol Arch Med Wewn; 2013; 123(4):191-2. PubMed ID: 23648814
[No Abstract] [Full Text] [Related]
13. Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493.
Drugs R D; 2003; 4(6):349-51. PubMed ID: 14584963
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
Nakanishi S; Fukagawa M
Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
[TBL] [Abstract][Full Text] [Related]
15. [Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism].
Hanba Y; Ooura M; Negi S; Shigematsu T
Clin Calcium; 2008 Jan; 18(1):81-8. PubMed ID: 18175876
[TBL] [Abstract][Full Text] [Related]
16. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].
Uemura K; Kakuta T
Clin Calcium; 2010 Jul; 20(7):1104-10. PubMed ID: 20585190
[TBL] [Abstract][Full Text] [Related]
17. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
Vestergaard P; Nielsen LR; Mosekilde L
Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
[TBL] [Abstract][Full Text] [Related]
18. Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means.
Drüeke TB
Pediatr Nephrol; 2005 Mar; 20(3):399-403. PubMed ID: 15662538
[TBL] [Abstract][Full Text] [Related]
19. Cinacalcet: benefit and cost.
Cohen E
Nephrol Dial Transplant; 2008 Apr; 23(4):1460; author reply 1460. PubMed ID: 18065795
[No Abstract] [Full Text] [Related]
20. [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].
Akiba T
Clin Calcium; 2007 May; 17(5):767-71. PubMed ID: 17471008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
